Myleran (Busulfan)

Busulfan, the active ingredient in Myleran, is an alkylating agent presented as an oral capsule for oral use. It is employed in the treatment of chronic myelogenous leukemia, myelodysplastic syndromes, and as part of conditioning regimens for hematopoietic stem cell transplantation. GNH USA supplies Myleran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Busulfan is an alkylating chemotherapy agent used in several hematologic conditions.

Chronic myelogenous leukemia: achieves disease control and remission by eradicating malignant leukemic cells. Myelodysplastic syndromes: reduces abnormal marrow proliferation and improves blood counts. Conditioning regimen for hematopoietic stem cell transplantation: provides myeloablation to allow successful engraftment of donor stem cells.

Busulfan may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting - Oral mucositis - Alopecia (hair loss) - Fever or chills

Serious or Rare Side Effects: - Pulmonary fibrosis or interstitial lung disease - Hepatic veno‑occlusive disease (VOD) - Seizures, especially at high plasma concentrations - Severe bone marrow suppression resulting in pancytopenia and infection risk

When using Busulfan, careful monitoring and risk mitigation are essential.

Monitor blood counts: perform regular complete blood count assessments. Assess liver function: evaluate hepatic enzymes before and during therapy. Avoid in pregnancy unless absolutely necessary: Busulfan is classified as Pregnancy Category D. Use anticonvulsant prophylaxis if high‑dose regimens are planned. Adjust dose in hepatic impairment: consider reduced dosing or increased monitoring. Store at ambient temperature: keep capsules in the original container, protect from moisture and direct sunlight.

Busulfan can interact with several medications, altering its efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other alkylating agents (e.g., cyclophosphamide) - Strong CYP2B6 inducers such as rifampin, which lower Busulfan exposure - Drugs that lower seizure threshold (e.g., bupropion)

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole) that increase Busulfan plasma levels - Acetaminophen, which may enhance hepatic toxicity - Phenytoin, which can reduce Busulfan concentrations